Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP4 | P49662 | 1/20 | 0.37 |
| ▸ | CASP5 | P51878 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4382180 | 0.98 | CHRM5 (0.64) | CHRM5ADRA2CACHEGBA1SMN1; SMN2 | |
| SCHEMBL528918 | 0.98 | CHRM5 (0.62) | CHRM5ADRA2CACHEGBA1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3551950 | 0.95 | CHRM5 (0.60) | CHRM5ADRA2CACHEGBA1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28737630 | 0.95 | CHRM5 (0.60) | CHRM5ADRA2CACHEGBA1SMN1; SMN2 | |
| SCHEMBL3062251 | 0.93 | CHRM5 (0.56) | CHRM5ADRA2CACHEGBA1SMN1; SMN2 | |
| SCHEMBL13660822 | 0.92 | CHRM5 (0.57) | CHRM5ADRA2CACHEGBA1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1994562 | 0.91 | CHRM5 (0.54) | CHRM5ADRA2CACHEGBA1SMN1; SMN2 | |
| SCHEMBL14422030 | 0.88 | GBA1 (0.48) | CHRM5ADRA2CACHEGBA1SMN1; SMN2 | |
| SCHEMBL2462435 | 0.87 | CHRM5 (0.56) | CHRM5ADRA2CACHEGBA1SMN1; SMN2 | |
| SCHEMBL13950187 | 0.87 | CHRM5 (0.56) | CHRM5ADRA2CACHEGBA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| CN-1203069-C | Substituted piperidines, medicaments containing these compounds, and methods for production thereof | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-05-25 | — | — | CN | claimed |
| US-20030212057-A1 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-13 | — | — | US | claimed |
| CN-1414960-A | Substituted piperidines, medicaments containing these compounds, and methods for production thereof | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-04-30 | — | — | CN | claimed |
| EP-0333427-B1 | Heterocyclic derivatives | SMITHKLINE BEECHAM FARMA (IT) | 1995-08-23 | — | — | EP | claimed |
| EP-0333427-A1 | Heterocyclic derivatives | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1989-09-20 | — | — | EP | claimed |
| US-20240382600-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | NOVARTIS AG (CH) | 2024-11-21 | — | — | US | disclosed |
| WO-2024054591-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054602-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20240051946-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2024-02-15 | — | — | US | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-20230183222-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| EP-0333427-A1 | Heterocyclic derivatives | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1989-09-20 | — | — | EP | disclosed |
| US-4396765-A | ANTIASTHMATICS, BRONCHODILATORS | STERLING DRUG INC. (US) | 1983-08-02 | — | — | US | disclosed |
| US-4339576-A | Anti-asthmatic, anti-allergic, anti-cholinergic, bronchodilator and anti-inflammatory 1-[(benzoylphenyl)-lower-alkyl]piperidines and analogs thereof | STERLING DRUG INC. (US) | 1982-07-13 | — | — | US | disclosed |
| EP-0052311-A1 | 1-((Benzoylphenyl) - lower-alkyl) piperidines and carbinol analogs and preparation thereof | STERLING DRUG INC. (US) | 1982-05-26 | — | — | EP | disclosed |
| US-4304911-A | ANTIHISTAMINES, ANTIALLERGENS, ANTICHOLINERGIC AGENTS, ANTIINFLAMMATORY AGENTS, BRONCHODILATOR AGENTS, AND ANALGESICS | STERLING DRUG INC. (US) | 1981-12-08 | — | — | US | disclosed |
| EP-0024356-A1 | Pharmaceutical composition for treating a condition exhibiting pain, fever, and inflammation comprising 2-(substituted piperidinomethyl) propane- and propene nitriles | MERCK & CO. INC. (US) | 1981-03-04 | — | — | EP | disclosed |
| US-4254131-A | Treatment of pain, fever, and inflammation with compositions containing 2-(substitutedpiperidinomethyl)propane and propene nitriles | MERCK & CO., INC. (US) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382600-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | YAP1, JMJD7, TOR1AIP1 | CHRM5 4868/4885ADRA2C 4769/4885ACHE 4312/4885 |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | CHRM5 4105/4885ADRA2C 2057/4885ACHE 4474/4885 |
| US-20030212057-A1 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | CALCA, CALCRL, P2RY1 | CHRM5 441/4885ADRA2C 36/4885ACHE 1225/4885 |
| US-20230183222-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | CHRM5 1381/4885ADRA2C 23/4885ACHE 282/4885 |
| US-20240051946-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | CHRM5 4863/4885ADRA2C 4383/4885ACHE 4806/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | CHRM5 4105/4885ADRA2C 2057/4885ACHE 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.